Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential…
Dr. Buchanan will helm Belharra’s research organization as the company progresses its lead immunology and oncology programs, advances activities with…
– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to…
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase…
PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader…
HUNTSVILLE, Ala., Jan. 9, 2025 /PRNewswire/ -- healthŌme®, Inc., a pioneering genomics-based precision health management company, today announced its renaming…
More than 50 peer-reviewed articles published in fiscal year 2024, bringing all-time number to nearly 450 KENNEDY SPACE CENTER, Fla.,…
VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased…
SALT LAKE CITY, Jan. 9, 2025 /PRNewswire/ -- Survivor Healthcare, a specialty provider of primary supportive care for cancer patients, has…
SAN FRANCISCO and STRASBOURG, France, Jan. 9, 2025 /PRNewswire/ -- Caresyntax, the world-leading developer of surgical intelligence platforms and Qaelon…